lung cancer

by Agency for Science, Technology and Research (A*STAR), Singapore edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Genome-wide RNAi screen to identify candidate stabilizers of EGFR mutants. Credit: Science Advances (2026). DOI: 10.1126/sciadv.adv3980 Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become […]

by The University of Hong Kong edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Tumor suppression in vivo. In animal models, LS-170 treatment significantly reduced tumor volume, demonstrating its strong anti-cancer potential. Credit: Nature Chemical Biology (2026). DOI: 10.1038/s41589-025-02132-7 A research team has made a breakthrough in epigenetic drug discovery. The researchers

by University of Florida edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Cell Reports Medicine (2025). DOI: 10.1016/j.xcrm.2025.102519 UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a

by Mass General Brigham edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Artem Podrez from Pexels A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will

Study identifies weak point in cancer cells as therapeutic perspective Peer-Reviewed Publication Medical University of Vienna A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer. The study shows that a combination of two well-studied classes of drugs – ERBB

by University of Miami Leonard M. Miller School of Medicine edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Credit: Pixabay/CC0 Public Domain A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises

by University of California, San Francisco edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes Credit: Cell Stem Cell (2025). DOI: 10.1016/j.stem.2025.10.005 Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone by since cell biologist Judith Campisi, Ph.D., paradoxically demonstrated that these same cells can promote cancer growth in

Study in Molecular Therapy Oncology shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types Peer-Reviewed Publication CHRISTIANACARE GENE EDITING INSTITUTE IMAGE: KELLY BANAS, PHD, LEAD AUTHOR OF THE STUDY AND ASSOCIATE DIRECTOR OF RESEARCH AT THE GENE EDITING INSTITUTE view more  CREDIT: MEGAN MCGURIMAN, CHRISTIANACARE WILMINGTON, DEL. (November 14, 2025) –

by University of Texas MD Anderson Cancer Center edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes Spatial transcriptomics analysis with super-pixel resolution of a human lung precursor lesion (red dash border), with colors representing different gene programs that are spatially mapped. Credit: Humam Kadara, Ph.D. By creating high-resolution cellular and molecular visual maps of lung cancer